Travere Therapeutics, Inc. (TVTX)
- Sector
- Biotechnology
- Last price
- $50.84
- As of
Kresmion compiles this page from TVTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Travere Therapeutics, Inc. (TVTX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
See the full TVTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TVTX on one page. Preview it with sample data, then open it live with a free account.
Preview the TVTX dossierActive events for TVTX
- highInsider cluster: sales
3 insiders at TVTX sold $38.1M this week
- highInsider cluster: sales
7 insiders at TVTX sold $65.0M this week
- high13F: funds added
6 tracked funds increased TVTX this 2026Q2, institutional consensus
- high13F: funds added
7 tracked funds increased TVTX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +141% to TVTX (2026Q2)
FREE, NO ACCOUNT
Every event on TVTX, as it fires
You are seeing 5 of 21 events recorded on TVTX since 2026-06-05.
The five above landed across 4 days. The other 16 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TVTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 89422G107 · 2026Q2 | $104.1M | 0.14% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 89422G107 · 2026Q2 | $88.9M | 0.06% | , |
| D. E. Shaw & Co., Inc.CUSIP 89422G107 · 2026Q2 | $81.8M | 0.04% | , |
| Point72 Asset Management, L.P.CUSIP 89422G107 · 2026Q2 | $27.2M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 89422GAB3 · 2026Q2 | $13.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 89422GAB3 · 2026Q2 | $7.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 89422GAB3 · 2026Q2 | $5.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 89422G107 · 2026Q2 | $4.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 89422G107 · 2026Q2 | $2.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 89422GAB3 · 2026Q2 | $588K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TVTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
TVTX against its peers
TVTX's operating margin of -12.8% ranks in the 57th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | TVTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 491M USD | 190M USD | 59 | 15 |
| Gross margin | 97.9% | 85.2% | 92 | 5 |
| Operating margin | -12.8% | -57.2% | 57 | 14 |
| Net margin | -5.2% | -66.2% | 57 | 14 |
| Return on equity | -22.2% | -30.3% | 69 | 23 |
Peers (25): DNTH, DFTX, EWTX, CRSP, LEGN, APLS.D, PTCT, SRRK, ERAS, RLAY, MIRM, COGT, CGON, VCYT, ARQT, CPRX.D, BLTE, MANE, IMVT, KOD, TNGX, IRON, CNTA.D, RYTM, ORKA. Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (TVTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TVTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TVTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.